Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for
cancer detection and intervention. Here, we use a machine learning model for detecting …

Rationale: Cell-free DNA (cfDNA) analysis holds promise for early detection of lung cancer
and benefits patients with higher survival. However, the detection sensitivity of previous …

Background Blood-based methods using cell-free DNA (cfDNA) are under development as
an alternative to existing screening tests. However, early-stage detection of cancer using …

Liver cancer is a major cause of cancer mortality worldwide. Screening individuals at high
risk, including those with cirrhosis and viral hepatitis, provides an avenue for improved …

Early detection can benefit cancer patients with more effective treatments and better
prognosis, but existing early screening tests are limited, especially for multi-cancer …

Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …

Circulating tumor DNA (ctDNA) is emerging as a key potential biomarker for post-diagnosis
surveillance but it may also play a crucial role in the detection of pre-clinical cancer. Small …

Circulating cell-free DNA (ccfDNA) has emerged as a promising diagnostic tool in oncology.
Identification of tumour-derived ccfDNA (ie circulating tumour DNA [ctDNA]) provides non …

Cell-free DNA in the blood provides a non-invasive diagnostic avenue for patients with
cancer. However, characteristics of the origins and molecular features of cell-free DNA are …

Radiologic screening of high-risk adults reduces lung-cancer-related mortality,; however, a
small minority of eligible individuals undergo such screening in the United States,. The …